LBI Embolectomy System
Commercial- Indications
- Peripheral artery disease
Company intelligence / Profile preview
Lumen Biomedical developed and commercialized interventional medical devices for embolic protection and thrombus removal. Its main products were the FiberNet Embolic Protection System for use during endovascular interventions such as carotid stenting, and the Xtract thrombus aspiration catheter for acute myocardial infarction. The company received FDA clearance for its devices but faced financial challenges, leading to the sale of its Xtract product line to Volcano Corporation in 2010. The company's current operational status is unclear but it appears inactive or defunct as an independent entity.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Lumen Biomedical.